1036389-05-5

Basic information

• Product Name: 5-amino-2-bromo-3-fluorobenzoate methyl ester
• Synonyms: 5-amino-2-bromo-3-fluorobenzoate methyl ester
• CAS NO: 1036389-05-5
• Molecular Weight: 248.051
• Mol File: 1036389-05-5.mol

Chemical Properties

• CAS DataBase Reference: 5-amino-2-bromo-3-fluorobenzoate methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-amino-2-bromo-3-fluorobenzoate methyl ester(1036389-05-5)
• EPA Substance Registry System: 5-amino-2-bromo-3-fluorobenzoate methyl ester(1036389-05-5)

Safety Data

• Hazardous Substances Data: 1036389-05-5(Hazardous Substances Data)

Upstream product

• 67-56-1 methanol 
• 881415-28-7 2-bromo-3-fluoro-5-nitrobenzoic acid 
• 881415-27-6 2-bromo-3-fluoro-6-nitrobenzoic acid 
• 132715-69-6 2-bromo-3-fluoro-benzoic acid 
• 317-20-4 7-fluoro-1H-indole-2,3-dione 

Downstream Products

• 1036389-07-7 5-amino-2-cyano-3-fluorobenzoate methyl ester 
• 1036390-98-3 6-amino-2-cyano-3-fluorobenzoate methyl ester 
• 1036389-09-9 6-amino-4-fluoro-isoindoline-1-one 
• 1036389-11-3 C₁₈H₁₇FN₂O₅ 

Relevant articles and documents

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.

A kind of diaryl hydanto?n derivatives, its preparation method, pharmaceutical composition and application

Provided are a compound as represented by formula I, or pharmaceutically acceptable salt, solvate, precursor drug, stereoisomer, tautomer, polymorph or metabolite thereof, pharmaceutical composition containing same, and uses thereof in the preparation of drugs for treating androgen receptor related diseases.

Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors

Inhibitors of Factor VIIa (FVIIa), a serine protease in the clotting cascade, have shown strong antithrombotic efficacy in preclinical thrombosis models with minimal bleeding liabilities. Discovery of potent, orally active FVIIa inhibitors has been largely unsuccessful because known chemotypes have required a highly basic group in the S1 binding pocket for high affinity. A recently reported fragment screening effort resulted in the discovery of a neutral heterocycle, 7-chloro-3,4-dihydroisoquinolin-1(2H)-one, that binds in the S1 pocket of FVIIa and can be incorporated into a phenylglycine FVIIa inhibitor. Optimization of this P1 binding group led to the first series of neutral, permeable FVIIa inhibitors with low nanomolar potency.

BICYCLIC LACTAM FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS

The present invention provides novel bicyclic lactams derivatives, and analogues thereof, of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, B, C, W, Y, Z1, Z2, Z3, Z4, R8, and R9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.